Donor lazaroid pretreatment improves viability of livers harvested from non-heart-beating rats
| Autor: | Hua Sheng Xu, William C. Stevenson, R. Scott Jones, Timothy L. Pruett |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
Pathology medicine.medical_specialty Antioxidant Lidocaine medicine.medical_treatment Ischemia Rats Sprague-Dawley Andrology Lipid peroxidation chemistry.chemical_compound Lactate dehydrogenase medicine Animals Bile Aspartate Aminotransferases Pregnatrienes Tissue Survival Chemotherapy L-Lactate Dehydrogenase business.industry General Medicine Metabolism medicine.disease Heart Arrest Liver Transplantation Rats Transplantation chemistry Surgery business medicine.drug |
| Zdroj: | The American Journal of Surgery. 171:113-117 |
| ISSN: | 0002-9610 |
| DOI: | 10.1016/s0002-9610(99)80084-1 |
| Popis: | Background Lazaroids are potent inhibitors of lipid peroxidation. Whether the compounds can benefit the liver procured from non-heart-beating donors (NHBDs) is unknown. Methods Donor rats were pretreated with lazaroid U74006F (4.5 mg/kg) 1 hour before cardiac arrest, and transplantation was performed in the rats with donor cardiac arrest from 0 to 60,100, 120,140, and 160 minutes as lazaroid pretreated groups. The same number of liver transplantations were done in each paired control group without donor lazaroid pretreatment. Recipient survival rates, bile secretion, serum enzymes, and a lidocaine metabolism test were analyzed. Results Donor lazaroid pretreatment significantly increased recipient 3-day survival rates in groups with 60,100, and 120 minutes of warm ischemia and 7-day survival with 60 minutes of warm ischemia. Also, the pretreatment increased bile secretion and reduced serum aspartate aminotransferase and lactate dehydrogenase levels in the lazaroid-pretreated groups. Conclusions Donor U74006F pretreatment improves viability of livers procured from NHBDs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect